Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurre…

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned ...
ascopubs.org

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.

Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma ...
Zacks Small Cap Research on MSN

MTVA: No evidence for changes in cardiovascular parameters in phase 1 trial of DA-1726

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Treatment with DA-1726 Shows No Evidence ...

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid ...

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across ...
ascopubs.org

A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma ...

Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Nasdaq

Monte Rosa Therapeutics Begins Phase 1 Study of MRT-8102 for Inflammatory Conditions with Initial Results Expected in H1 2026

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
Business Wire

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
The American Journal of Managed Care

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...